SIRT1 is highly expressed in brain metastasis tissues of non-small cell lung cancer (NSCLC) and in positive regulation of NSCLC cell migration

被引:1
|
作者
Han, Lin [1 ]
Liang, Xiao-Hua [2 ]
Chen, Li-Xin [1 ]
Bao, Shi-Min [1 ]
Yan, Zhi-Qiang [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Biol Sci, Ctr Expt Anim, Shanghai, Peoples R China
[2] Fudan Univ, Huashan Hosp, Dept Oncol, Shanghai 200433, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2013年 / 6卷 / 11期
关键词
Non-small cell lung cancer; brain metastasis; RNAi screening; epigenetics; SIRT1; TO-MESENCHYMAL TRANSITION; RADIATION-THERAPY; INVASION; TRANSCRIPTION; PROGRESSION; CARCINOMA; REPRESSION; CORTACTIN; PATHWAY; DISEASE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Brain metastases are a frequent and ongoing major complication of non-small cell lung cancer (NSCLC). To deepen our understanding to the underlying mechanisms by which NSCLC cells metastasize to brain and hence to improve the therapy, a high throughput RNAi screening with shRNA library of 153 epigenetic genes was subjected to A549, a NSCLC cell line with high migration ability, to examine the effects of these genes on cell migration by wound-healing assay. The screening results showed that knockdown of 2 genes (KDM5B and SIRT1) dramatically and specifically inhibits A549 migration but not affects the proliferation, which was subsequently confirmed through transwell migration assay. Furthermore, SIRT1 is found to be highly expressed in brain metastasis tissues of NSCLC, compared to the NSCLC tissues, suggesting that SIRT1 may play roles in brain metastasis of NSCLC. The relationship between SIRT1 expression and cell migration ability was further investigated in three NSCLC cell lines and the result indicated that SIRT1 expression is tightly correlated with cell migration ability. Collectively, our work provides potential biomarker and therapeutic target for brain metastasis of NSCLC.
引用
收藏
页码:2357 / +
页数:11
相关论文
共 50 条
  • [41] Role of microRNAs in the metastasis of non-small cell lung cancer
    Li, Shenglei
    Gao, Ming
    Li, Zongming
    Song, Lijie
    Gao, Xianzheng
    Han, Jing
    Wang, Feng
    Chen, Yongfang
    Li, WenCai
    Yang, Jianping
    Han, Xinwei
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2016, 21 : 998 - 1005
  • [42] Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)
    Fumihiro Tanaka
    Kazue Yoneda
    Surgery Today, 2016, 46 : 25 - 37
  • [43] Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Papachristos, A.
    Masinde, S.
    Davis, J. D.
    Gullo, G.
    Rietschel, P.
    Paccaly, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S308 - S309
  • [44] An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)
    Murphy, Ciara
    Gornes Pons, Gloria
    Keogh, Anna
    Ryan, Lisa
    Mccarra, Lorraine
    Jose, Chris Maria
    Kesar, Shagun
    Nicholson, Siobhan
    Fitzmaurice, Gerard J.
    Ryan, Ronan
    Young, Vincent
    Cuffe, Sinead
    Finn, Stephen P.
    Gray, Steven G.
    BIOMEDICINES, 2023, 11 (09)
  • [45] Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)
    Gerald Schmid-Bindert
    Targeted Oncology, 2013, 8 : 15 - 26
  • [46] Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC)
    Grossi, Francesco
    Tiseo, Marcello
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 58 (03) : 221 - 230
  • [47] Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)
    Guo, Shicheng
    Yan, Fengyang
    Xu, Jibin
    Bao, Yang
    Zhu, Ji
    Wang, Xiaotian
    Wu, Junjie
    Li, Yi
    Pu, Weilin
    Liu, Yan
    Jiang, Zhengwen
    Ma, Yanyun
    Chen, Xiaofeng
    Xiong, Momiao
    Jin, Li
    Wang, Jiucun
    Clinical Epigenetics, 2015, 7 : 2 - 9
  • [48] Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)
    Celine Mascaux
    Simon Ekman
    Christophe Dooms
    Frances A. Shepherd
    Current Respiratory Care Reports, 2013, 2 (1): : 1 - 9
  • [49] Phase II study of mitonafide in non-small cell lung cancer (NSCLC)
    Casado, A
    Rosell, R
    GarciaGomez, R
    DiazRubio, E
    PerezManga, G
    Font, A
    Benavides, A
    Martin, M
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (04) : 415 - 417
  • [50] Prognosis for non-small cell lung cancer patients with brain metastases
    Kim, Junghyun
    Lee, Sang-Min
    Yim, Jae-Jun
    Yoo, Chul Gyu
    Kim, Young Whan
    Han, Sung Koo
    Yang, Seok-Chul
    THORACIC CANCER, 2013, 4 (02) : 167 - 173